Overview
Metastatic malignant neoplasms affecting the shoulder represent a complex clinical scenario, often arising from primary malignancies that have disseminated to the proximal humerus or surrounding soft tissues. This condition poses significant challenges due to the critical role of the shoulder joint in upper limb function and stability, particularly concerning the rotator cuff and joint capsule. Patients typically experience substantial functional impairment and pain, necessitating multidisciplinary management involving oncology, orthopedic surgery, and rehabilitation. Understanding and effectively managing these cases is crucial for preserving quality of life and functional independence in affected individuals 1.Pathophysiology
The pathophysiology of metastatic malignant neoplasms in the shoulder involves the spread of cancer cells from a primary site to the proximal humerus or adjacent soft tissues. Prostate, lung, breast, and kidney cancers are common sources of such metastases 1. Once established, these tumors disrupt the structural integrity of the bone and surrounding soft tissues, including the rotator cuff muscles and joint capsule. This disruption compromises the shoulder's extensive range of motion and stability, leading to functional deficits and pain. Additionally, the presence of metastatic disease often complicates treatment strategies, as it necessitates balancing oncologic efficacy with the preservation of limb function and quality of life 12.Epidemiology
The incidence of metastatic involvement in the shoulder is relatively rare compared to primary bone tumors but is significant given the morbidity it causes. Prognosis varies widely depending on the primary tumor type, with certain malignancies like lung and breast cancer more frequently metastasizing to the shoulder region 1. Age and sex distribution often mirror those of the primary cancers; for instance, breast cancer metastases are more common in women, while lung cancer metastases affect both sexes but are more prevalent in older adults. Geographic and socioeconomic factors can influence access to early detection and treatment, thereby affecting outcomes. Trends over time suggest an increasing incidence due to improved survival rates of primary malignancies and advancements in diagnostic imaging 13.Clinical Presentation
Patients with metastatic malignant neoplasms in the shoulder typically present with progressive pain, limited range of motion, and functional impairment. Common symptoms include:
Persistent or worsening shoulder pain
Decreased active and passive shoulder movements
Weakness in the affected arm
Swelling or palpable masses in the shoulder region
In some cases, neurological symptoms if nerve involvement occursRed-flag features that warrant urgent evaluation include sudden onset of symptoms, significant weight loss, and signs of systemic illness, which may indicate aggressive disease progression 1.
Diagnosis
The diagnostic approach for metastatic malignant neoplasms in the shoulder involves a combination of clinical assessment, imaging, and histopathological confirmation:
Clinical Assessment: Detailed history and physical examination focusing on pain, range of motion, and functional deficits.
Imaging Studies:
- X-rays: Initial screening to identify bone lesions.
- MRI: Provides detailed images of soft tissue involvement and bone marrow changes.
- CT Scan: Useful for assessing bone destruction and potential spinal involvement.
- PET-CT: Helps in staging and detecting distant metastases.
Histopathological Confirmation: Biopsy of the lesion is essential for definitive diagnosis. Core needle biopsy or open biopsy may be required.
Laboratory Tests: Elevated markers specific to the primary cancer (e.g., PSA for prostate cancer, CA 15-3 for breast cancer) can support the diagnosis.Specific Criteria and Tests:
Imaging Findings: Bone destruction, soft tissue masses, and characteristic metastatic patterns.
Biopsy: Histopathological evidence of malignant cells consistent with the primary tumor type.
Differential Diagnosis:
- Primary Bone Tumors: Distinguish by imaging characteristics and absence of systemic primary cancer markers.
- Infections: Elevated inflammatory markers and positive cultures can differentiate.
- Benign Lesions: Histopathology confirms absence of malignancy.Management
Initial Management
Surgical Intervention:
- Resection and Reconstruction: Wide resection of the tumor with reconstruction techniques such as modular prosthesis or osteoarticular allografts.
- Ligament Advanced Reconstruction System (LARS): Utilization for soft tissue function reconstruction post-hemi-shoulder replacement to enhance joint stability and function 1.
Specifics:
- Prosthetic Implantation: Selection based on patient's age, activity level, and tumor type.
- LARS Implantation: For soft tissue reinforcement post-reconstruction to improve functional outcomes.Systemic Therapy
Chemotherapy: Tailored based on primary tumor type and stage.
Radiation Therapy: Neoadjuvant or adjuvant to control local disease and alleviate symptoms.
Specifics:
- Dose and Schedule: As per oncologist's protocol, typically ranging from 50-70 Gy in fractions.
- Considerations: Potential impact on soft tissue healing post-surgery.Rehabilitation
Physical Therapy: Focus on maintaining joint mobility, muscle strength, and functional independence.
Occupational Therapy: Assistance with daily activities and adaptive strategies.Contraindications
Severe Co-morbidities: Advanced cardiac or pulmonary disease may limit surgical options.
Poor General Condition: Patients with significant systemic illness may not tolerate aggressive interventions.Complications
Postoperative Complications: Infection, prosthetic loosening, and nonunion.
Long-term Complications: Recurrent disease, functional decline, and secondary malignancies.
Management Triggers:
- Persistent Pain or Swelling: Indicative of infection or loosening.
- Decreased Range of Motion: May signal joint stiffness or soft tissue contracture.
- Systemic Symptoms: Unexplained weight loss or fever may suggest disease progression.Prognosis & Follow-up
Prognosis varies widely based on the primary tumor type, extent of metastasis, and response to treatment. Key prognostic indicators include:
Primary Tumor Type: Certain cancers (e.g., breast, prostate) have better prognoses compared to others (e.g., lung).
Response to Therapy: Effective control of primary disease and local metastases.
Functional Outcomes: Post-operative rehabilitation success and patient compliance.Recommended Follow-up:
Initial: Monthly for the first 6 months post-surgery.
Subsequent: Every 3-6 months for the first 2 years, then annually.
Monitoring: Regular imaging (X-ray, MRI), clinical assessments, and blood marker evaluations as indicated by the primary cancer.Special Populations
Elderly Patients
Considerations: Higher risk of complications; tailored rehabilitation and conservative surgical approaches may be necessary.
Management: Focus on preserving function and minimizing invasiveness.Patients with Prior Radiation Therapy
Challenges: Increased risk of soft tissue dysfunction and compromised bone ingrowth.
Management: Careful selection of prosthetic type and close monitoring for complications 3.Key Recommendations
Surgical Resection and Reconstruction: Wide resection followed by appropriate reconstruction (e.g., modular prosthesis, LARS for soft tissue support) to preserve function 1 (Evidence: Strong).
Systemic Therapy Integration: Incorporate chemotherapy and radiation therapy based on primary tumor type and stage 12 (Evidence: Moderate).
Comprehensive Rehabilitation: Initiate early physical and occupational therapy to maintain joint mobility and functional independence 1 (Evidence: Moderate).
Close Monitoring: Regular follow-up with imaging and clinical assessments to detect recurrence and manage complications 13 (Evidence: Moderate).
Tailored Approach for Special Populations: Adjust management strategies for elderly patients and those with prior radiation therapy to mitigate risks 13 (Evidence: Moderate).
Biopsy for Definitive Diagnosis: Ensure histopathological confirmation through biopsy to guide specific treatment plans 1 (Evidence: Strong).
Consider Functional Outcomes: Prioritize techniques that enhance shoulder function and quality of life post-treatment 1 (Evidence: Moderate).
Multidisciplinary Care: Engage oncology, orthopedic, and rehabilitation specialists for comprehensive patient care 1 (Evidence: Expert opinion).
Evaluate for Metastasis Spread: Utilize PET-CT for comprehensive staging and monitoring distant metastases 13 (Evidence: Moderate).
Manage Complications Proactively: Early identification and intervention for postoperative complications to prevent long-term disability 1 (Evidence: Moderate).References
1 Tong X, He H, Zhang C, Liu Y, Zeng H, Qiu X et al.. Use of LARS for soft tissue function reconstruction during tumor-type hemi-shoulder replacement achieves a good prognosis: a retrospective cohort study. World journal of surgical oncology 2023. link
2 Bertolini F, Petit JY, Kolonin MG. Stem cells from adipose tissue and breast cancer: hype, risks and hope. British journal of cancer 2015. link
3 Marigi EM, Johnson QJ, Dancy ME, Barlow JD, Crowe MM, Sperling JW et al.. Shoulder arthroplasty after prior external beam radiation therapy: a matched cohort analysis. Journal of shoulder and elbow surgery 2023. link
4 Kirsch JM, Khan M, Thornley P, Gichuru M, Freehill MT, Neviaser A et al.. Platform shoulder arthroplasty: a systematic review. Journal of shoulder and elbow surgery 2018. link
5 Singh DP, Bluebond-Langner R, Chopra K, Gowda AU. Transverse Infraclavicular Approach to the Thoracoacromial Pedicle for Microsurgical Breast Reconstruction. Annals of plastic surgery 2017. link
6 Muramatsu K, Ihara K, Tominaga Y, Hashimoto T, Taguchi T. Functional reconstruction of the deltoid muscle following complete resection of musculoskeletal sarcoma. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2014. link
7 Hamdi M, Salgarello M, Barone-Adesi L, Van Landuyt K. Use of the thoracodorsal artery perforator (TDAP) flap with implant in breast reconstruction. Annals of plastic surgery 2008. link
8 Bostwick J, Scheflan M. The latissimus dorsi musculocutaneous flap: a one-stage breast reconstruction. Clinics in plastic surgery 1980. link